Literature DB >> 19582882

Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden.

Sigurdur Y Kristinsson1, Magnus Björkholm, Lynn R Goldin, Cecilie Blimark, Ulf-Henrik Mellqvist, Anders Wahlin, Ingemar Turesson, Ola Landgren.   

Abstract

There are emerging data to suggest a role for genetic factors in the pathogenesis of multiple myeloma (MM). Based on small numbers, certain solid tumors have been reported to occur more frequently among blood relatives of patients with MM. Using population-based data, we assessed risks for hematologic malignancies, monoclonal gammopathy of undetermined significance (MGUS), and solid tumors among first-degree relatives of patients with MM. We included 13,896 patients with MM and 54,365 matched controls. Also we identified first-degree relatives of patients with MM (n = 37,838) and controls (n = 151,068). Using a marginal survival model, we estimated relative risks (RRs) and 95% confidence intervals (CIs) for hematologic and solid tumors among family members of patients with MM and controls as measures of familial aggregation. Compared with relatives of controls, relatives of patients with MM had an increased risk of developing MM (RR = 2.1; 95% CI 1.6-2.9), MGUS (2.1; 1.5-3.1), acute lymphoblastic leukemia (ALL) (2.1; 1.0-4.2), any solid tumor (1.1; 1.0-1.1) and bladder cancer (1.3; 1.0-1.5). No significantly increased risk was found for other hematologic or solid malignancies. Our findings support a role for a shared susceptibility (genetic, environmental or both) that predisposes to MM, MGUS, ALL and bladder cancer. (c) 2009 UICC.

Entities:  

Mesh:

Year:  2009        PMID: 19582882      PMCID: PMC2737604          DOI: 10.1002/ijc.24514

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  28 in total

1.  Methods for testing familial aggregation of diseases in population-based samples: application to Hodgkin lymphoma in Swedish registry data.

Authors:  R M Pfeiffer; L R Goldin; N Chatterjee; S Daugherty; K Hemminki; D Pee; L I X; M H Gail
Journal:  Ann Hum Genet       Date:  2004-09       Impact factor: 1.670

2.  Estimating effects of probands' characteristics on familial risk: I. Adjustment for censoring and correlated ages at onset.

Authors:  K Y Liang
Journal:  Genet Epidemiol       Date:  1991       Impact factor: 2.135

3.  Familial bladder cancer in the National Swedish Family Cancer Database.

Authors:  K Plna; K Hemminki
Journal:  J Urol       Date:  2001-12       Impact factor: 7.450

4.  A long-term study of prognosis in monoclonal gammopathy of undetermined significance.

Authors:  Robert A Kyle; Terry M Therneau; S Vincent Rajkumar; Janice R Offord; Dirk R Larson; Matthew F Plevak; L Joseph Melton
Journal:  N Engl J Med       Date:  2002-02-21       Impact factor: 91.245

Review 5.  Familial multiple myeloma: a family study and review of the literature.

Authors:  H T Lynch; W G Sanger; S Pirruccello; B Quinn-Laquer; D D Weisenburger
Journal:  J Natl Cancer Inst       Date:  2001-10-03       Impact factor: 13.506

6.  Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later.

Authors:  Robert A Kyle; Terry M Therneau; S Vincent Rajkumar; Dirk R Larson; Matthew F Plevak; L Joseph Melton
Journal:  Mayo Clin Proc       Date:  2004-07       Impact factor: 7.616

7.  Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden.

Authors:  Ola Landgren; Sigurdur Y Kristinsson; Lynn R Goldin; Neil E Caporaso; Cecilie Blimark; Ulf-Henrik Mellqvist; Anders Wahlin; Magnus Bjorkholm; Ingemar Turesson
Journal:  Blood       Date:  2009-01-30       Impact factor: 22.113

Review 8.  Advances in biology of multiple myeloma: clinical applications.

Authors:  Teru Hideshima; P Leif Bergsagel; W Michael Kuehl; Kenneth C Anderson
Journal:  Blood       Date:  2004-04-15       Impact factor: 22.113

Review 9.  Familial immunopathies: report of nine families and survey of literature.

Authors:  Z A Zawadzki; Y Aizawa; M A Kraj; A R Haradin; B Fisher
Journal:  Cancer       Date:  1977-11       Impact factor: 6.860

10.  Multiple myeloma in a pair of monozygotic twins: the first reported case.

Authors:  I R Judson; E Wiltshaw; A C Newland
Journal:  Br J Haematol       Date:  1985-07       Impact factor: 6.998

View more
  36 in total

1.  Familial aggregation of acute myeloid leukemia and myelodysplastic syndromes.

Authors:  Lynn R Goldin; Sigurdur Y Kristinsson; Xueying Sharon Liang; Asa R Derolf; Ola Landgren; Magnus Björkholm
Journal:  J Clin Oncol       Date:  2011-12-12       Impact factor: 44.544

2.  Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women.

Authors:  Ola Landgren; S Vincent Rajkumar; Ruth M Pfeiffer; Robert A Kyle; Jerry A Katzmann; Angela Dispenzieri; Qiuyin Cai; Lynn R Goldin; Neil E Caporaso; Joseph F Fraumeni; William J Blot; Lisa B Signorello
Journal:  Blood       Date:  2010-04-26       Impact factor: 22.113

Review 3.  Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myeloma.

Authors:  Brendan M Weiss; W Michael Kuehl
Journal:  Expert Rev Hematol       Date:  2010-04       Impact factor: 2.929

Review 4.  The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network.

Authors:  Niels W C J van de Donk; Antonio Palumbo; Hans Erik Johnsen; Monika Engelhardt; Francesca Gay; Henrik Gregersen; Roman Hajek; Martina Kleber; Heinz Ludwig; Gareth Morgan; Pellegrino Musto; Torben Plesner; Orhan Sezer; Evangelos Terpos; Anders Waage; Sonja Zweegman; Hermann Einsele; Pieter Sonneveld; Henk M Lokhorst
Journal:  Haematologica       Date:  2014-03-21       Impact factor: 9.941

Review 5.  Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies.

Authors:  Sigurdur Y Kristinsson; Lynn R Goldin; Magnus Björkholm; Jill Koshiol; Ingemar Turesson; Ola Landgren
Journal:  Haematologica       Date:  2009-07-07       Impact factor: 9.941

Review 6.  Precursors to lymphoproliferative malignancies.

Authors:  Lynn R Goldin; Mary L McMaster; Neil E Caporaso
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-04       Impact factor: 4.254

Review 7.  Monoclonal gammopathy of undetermined significance and smoldering myeloma: new insights into pathophysiology and epidemiology.

Authors:  Ola Landgren
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2010

8.  A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.

Authors:  Zhaohui Du; Niels Weinhold; Gregory Chi Song; Kristin A Rand; David J Van Den Berg; Amie E Hwang; Xin Sheng; Victor Hom; Sikander Ailawadhi; Ajay K Nooka; Seema Singhal; Karen Pawlish; Edward S Peters; Cathryn Bock; Ann Mohrbacher; Alexander Stram; Sonja I Berndt; William J Blot; Graham Casey; Victoria L Stevens; Rick Kittles; Phyllis J Goodman; W Ryan Diver; Anselm Hennis; Barbara Nemesure; Eric A Klein; Benjamin A Rybicki; Janet L Stanford; John S Witte; Lisa Signorello; Esther M John; Leslie Bernstein; Antoinette M Stroup; Owen W Stephens; Maurizio Zangari; Frits Van Rhee; Andrew Olshan; Wei Zheng; Jennifer J Hu; Regina Ziegler; Sarah J Nyante; Sue Ann Ingles; Michael F Press; John David Carpten; Stephen J Chanock; Jayesh Mehta; Graham A Colditz; Jeffrey Wolf; Thomas G Martin; Michael Tomasson; Mark A Fiala; Howard Terebelo; Nalini Janakiraman; Laurence Kolonel; Kenneth C Anderson; Loic Le Marchand; Daniel Auclair; Brian C-H Chiu; Elad Ziv; Daniel Stram; Ravi Vij; Leon Bernal-Mizrachi; Gareth J Morgan; Jeffrey A Zonder; Carol Ann Huff; Sagar Lonial; Robert Z Orlowski; David V Conti; Christopher A Haiman; Wendy Cozen
Journal:  Blood Adv       Date:  2020-01-14

Review 9.  Smoldering (asymptomatic) multiple myeloma: revisiting the clinical dilemma and looking into the future.

Authors:  Adam J Waxman; Michael Kuehl; Arun Balakumaran; Brendan Weiss; Ola Landgren
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2010-08

Review 10.  Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates.

Authors:  Sigurdur Yngvi Kristinsson; Ola Landgren; Vincent S Rajkumar
Journal:  Cancer J       Date:  2009 Nov-Dec       Impact factor: 3.360

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.